Prestige Consumer Healthcare Q3 revenue rises 2.7%; raises full-year EPS outlook
Prestige Consumer Healthcare reported third-quarter fiscal 2025 revenue of $290.3 million, up 2.7%, with diluted EPS of $1.22 versus $1.06 a year earlier. The company raised its fiscal 2025 adjusted diluted EPS outlook to approximately $4.50 from $4.40 to $4.46, and narrowed its revenue outlook to $1,128 million to $1,132 million. Nine-month revenue declined 0.8%, and third-quarter free cash flow fell, so shareholders gain from higher earnings guidance but see mixed trends in sales and cash flow.
Key points
- Q3 revenue $290.3 million, up 2.7% from $282.7 million; diluted EPS $1.22 versus $1.06
- Nine-month revenue $841.2 million, down 0.8%; non-GAAP adjusted diluted EPS $3.20 versus $3.19
- FY2025 adjusted diluted EPS outlook raised to approximately $4.50 from $4.40 to $4.46; revenue outlook $1,128 million to $1,132 million
- Q3 non-GAAP free cash flow $63.5 million versus $69.5 million; net debt about $0.9 billion, leverage 2.5x
The filing
Written by AI on Nov 8, 2026, 1:55 AM ET, from this filing only. Written later: this filing was briefed after the fact, when past filings were added to the site, so the brief may be read with hindsight; the filing itself is the record of what was known on February 06, 2025.
Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.